Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Inventory (2022 - 2025)

Atara Biotherapeutics' Change in Inventory history spans 4 years, with the latest figure at -$10.7 million for Q1 2025.

  • For Q1 2025, Change in Inventory fell 267.06% year-over-year to -$10.7 million; the TTM value through Dec 2025 reached -$10.7 million, down 340.3%, while the annual FY2025 figure was -$10.7 million, 340.3% down from the prior year.
  • Change in Inventory reached -$10.7 million in Q1 2025 per ATRA's latest filing, down from $160000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $6.4 million in Q1 2024 to a low of -$10.7 million in Q1 2025.
  • Average Change in Inventory over 4 years is $348500.0, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Change in Inventory: skyrocketed 96.41% in 2023, then crashed 275.51% in 2024.
  • A 4-year view of Change in Inventory shows it stood at $1.6 million in 2022, then surged by 96.41% to $3.1 million in 2023, then crashed by 94.86% to $160000.0 in 2024, then crashed by 6759.38% to -$10.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Change in Inventory are -$10.7 million (Q1 2025), $160000.0 (Q4 2024), and -$4.8 million (Q3 2024).